Key Takeaways
- Commercial readiness before Phase III is primarily about decisions and knowledge—not commercial headcount.
- Leadership should understand the patient journey, market reality, competitive landscape and major access assumptions.
- Clinical and commercial strategy should increasingly inform one another.
- The company should begin defining what capabilities it may eventually need to build.
- Major unresolved commercial assumptions should be visible to leadership and the board.
Phase III is not the point at which commercialization begins. By the time an emerging biotechnology company enters pivotal development, many assumptions that will shape future commercial success should already be visible, tested or actively being investigated.
The objective is not to build a complete commercial organization years before approval.
It is to ensure that critical commercial questions are not being deferred until the company has fewer strategic options.
Phase III Changes the Nature of Commercial Risk
Early biotechnology organizations are necessarily science-driven.
Capital, leadership attention and organizational capability focus on advancing the asset through development.
That is appropriate.
The risk arises when commercial thinking is postponed because the company has not yet become a commercial organization.
Commercial decisions exist long before sales representatives are hired.
Clinical endpoints can influence future positioning. Indication sequence can influence market opportunity. Evidence strategy can influence physician confidence and payer discussions. Patient identification can influence the scale and design of the future organization. Competition developing today may define the market at launch.
By Phase III, these considerations increasingly become interconnected.
The company does not need every answer.
It does need to know which questions could materially change its strategy.
1. Understand the Real Patient Opportunity
Prevalence is the beginning of market understanding, not the conclusion.
Before Phase III, leadership should have a progressively clearer view of diagnosed patients; eligible patients; treatment patterns; diagnostic delay; referral pathways; specialist concentration; Centers of Excellence; geographic concentration; and patient movement through the healthcare system.
The commercial opportunity is defined not only by how many patients may have a disease, but by how many can realistically be identified, reached, treated and supported.
This distinction is especially important in rare disease and specialized markets.
2. Understand How Treatment Decisions Are Made
A therapy is commercialized within an existing system.
Leadership should understand who influences that system—who diagnoses, who initiates therapy, who refers, which specialists influence broader clinical practice, which academic institutions matter, how concentrated prescribing is, what evidence changes physician behavior and which practical barriers could prevent adoption.
This knowledge later shapes Medical Affairs, commercial field design, market development and launch execution.
3. Pressure-Test Product Differentiation
Clinical success is essential.
Commercial success requires understanding what that clinical profile means within actual practice—how the product may be positioned, what current therapies accomplish, what unmet need remains, what future competitors could change, which data matter most to physicians, what could limit differentiation and which evidence gaps remain.
The competitive environment at launch may be very different from the market observed when development began.
Commercial strategy therefore needs to look forward.
4. Introduce Market Access Thinking Early
FDA approval establishes that a product may enter the market.
It does not ensure that patients will be able to receive it.
By Phase III, the company should increasingly understand potential payer requirements, reimbursement dynamics, prior authorization, specialty pharmacy needs, patient support requirements, treatment logistics, affordability concerns and evidence gaps relevant to access.
The objective is not to finalize pricing years in advance.
It is to avoid discovering late that important evidence or infrastructure requires more lead time than the organization has available.
5. Understand What the Commercial Organization May Need to Become
Commercial readiness before Phase III does not require building the final organization.
It does require beginning to understand it.
A concentrated rare disease market may require a very different model from a broader specialty market.
Leadership should begin evaluating commercial leadership requirements, Medical Affairs scale, Market Access requirements, field structure, commercial operations, patient services, analytics, distribution, specialty pharmacy, training and launch governance.
This creates an initial capability roadmap.
6. Decide Which Commercial Capabilities Must Exist Internally
Emerging companies frequently face a build-versus-outsource decision.
Not every capability needs to reside internally.
But leadership should determine which capabilities are strategically important enough to own—where institutional knowledge is critical, which relationships require internal continuity, what capabilities differentiate the company, which activities specialist partners can perform efficiently and what must remain under executive control.
These decisions affect cost, recruitment and launch timing.
7. Connect Clinical Development and Commercial Strategy
Commercial involvement in development should not mean promotional influence over science.
It means ensuring leadership understands the downstream consequences of development decisions.
Commercial questions can help illuminate which patient populations matter, which evidence may influence adoption, which endpoints matter in practice, where competitive differentiation may emerge, how indication sequence influences opportunity and what evidence future stakeholders may require.
The stronger model is not Clinical versus Commercial.
It is an organization making integrated decisions while maintaining appropriate functional responsibilities.
8. Give the Board Visibility Into Commercial Assumptions
By Phase III, boards should increasingly understand the assumptions behind future commercialization.
This does not require operational launch management.
It does require visibility into the addressable market, remaining uncertainties, material commercial risks, required capabilities, investment timing, readiness delays and decisions that cannot be deferred.
Commercial readiness becomes an enterprise issue as development advances.
Commercial Readiness Is Not Commercial Spending
Companies sometimes resist early commercial planning because they equate it with building an expensive organization prematurely.
That is the wrong comparison.
Early commercial readiness is primarily about learning, judgment and sequencing.
The company should spend when capabilities are required.
But it should understand what those capabilities are well before the moment they must become operational.
A commercial plan developed too early can evolve.
A commercial requirement discovered too late may leave few options.
A Practical Leadership Test
Before Phase III, leadership should be able to explain:
- Who are the realistically addressable patients?
- How are they diagnosed and referred?
- Who influences treatment?
- What will differentiate the therapy?
- What evidence remains commercially important?
- What could prevent access?
- What organizational capabilities may be required?
- Which capabilities should be internal?
- What major commercial uncertainties remain?
- Which decisions become expensive if delayed?
If the organization cannot answer these questions, that does not automatically indicate failure.
It indicates where commercial learning should focus next.
Conclusion
Commercial readiness before Phase III is not about behaving like a commercial-stage pharmaceutical company before the science is mature.
It is about ensuring commercial reality has a seat at the table while important strategic options are still available.
The strongest emerging biotechnology companies do not attempt to predict every detail of the future.
They identify the assumptions that matter most, test them progressively and build capabilities when the evidence justifies investment.
That creates a more disciplined path from scientific progress to commercial readiness.
Assess Your Commercial Readiness
Preparing for pivotal development or a first commercial launch?
Speak with PharmaKonsult about the commercial decisions that should be addressed while strategic options remain open.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
